WebOtologic Pharmaceutics: Developing therapeutic solutions for hearing health. Auditus: a clinical stage asset designed to reduce acute acoustic trauma. This asset is licensed to Oblato. Autigen: a preclinical program focused on regrowing the sensory hairs cells within the cochlear. The is a joint collaboration with Boehringer Ingelheim WebApr 3, 2014 · OKLAHOMA CITY, April 3, 2014 /PRNewswire/ -- Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc., announced today that it has co-led a $4.1 million Series A private equity financing of Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and …
Otologic Pharmaceutics, Inc. successfully completes Phase I trial …
WebOct 1, 2024 · About Otologic Pharmaceutics, Inc. OPI’s exploration of innovative therapies to treat hearing and balance disorders has led to product candidates aimed at both chronic and acute hearing loss. The loss of sensory hair cells commonly causes loss in … WebOtologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing … sql managed instance virtual cluster
Otologic Pharmaceutics VentureRadar
WebOct 1, 2024 · About Otologic Pharmaceutics, Inc. OPI’s exploration of innovative therapies to treat hearing and balance disorders has led to product candidates aimed at both chronic … WebFor the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports … Web17 Feb 2024 Disufenton/acetylcysteine is still in early research phase for Tinnitus in USA (PO, Capsule) (Otologic pharmaceutics pipeline, February 2024) ... (PO), before Febraury 2024 (Otologic pharma pipeline, February 2024) Subscriber content You need to be a logged in subscriber to view this content. If ... sql managed instance hci